Last updated: 2026-09-05 13:01:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
uniQure N.V. (QURE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $44.50, with a market capitalization of $3.11B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.73 to $71.50. This page covers its latest market performance, valuation, price trends and company information.
$3.11B | |
$44.91 | |
$82.49 | |
$3.73 | |
$44.86 | |
886.70K | |
1.83M | |
-- | |
$71.50 | |
$8.73 | |
-- | |
-- |
uniQure N.V. (QURE) last closed at $44.86 as of 2026-09-04 23:31:00, unchanged from the previous close of $44.86.
During the latest regular trading session, QURE traded between $3.73 and $82.49, with a volume of 886.70K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, uniQure N.V. (QURE) moved from $49.56 to $44.50, representing a decline of 10.21% ($5.06).
The stock traded between $43.90 and $51.03 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.26 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 57.0%
QURE is currently trading at $44.50, placing it 57.0% of the way from its 52-week low of $8.73 to its 52-week high of $71.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 221 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of uniQure N.V. (QURE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.